ARTICLE | Company News
Palatin other research news
October 14, 1996 7:00 AM UTC
PLTN received a $100,000 Phase I SBIR from the NIH to develop RC-160, an analog to somatostatin (a cell growth inhibiting hormone), for use in identifying breast and prostate tumors. PLTN tags RC-160 ...